GeoVax Labs, Inc., a clinical-stage biotechnology company, has issued a pressing call for the United States to bolster its pandemic preparedness and biodefense capabilities. Highlighting the global spread of Mpox, the emergence of immune-evasive COVID-19 variants, and the reliance on foreign vaccine supplies, GeoVax underscores the critical need for domestic solutions to safeguard public health.
The company's vaccine platform features two key candidates: GEO-MVA for Mpox and smallpox, and GEO-CM04S1, a next-generation COVID-19 vaccine aimed at providing robust protection for immunocompromised individuals. These developments come at a time when the Strategic National Stockpile's dependence on a single foreign supplier for Mpox vaccine raises concerns about the nation's readiness to respond to health emergencies.
Recent developments, including the spread of Clade I Mpox outbreaks and the dominance of the NB.1.8.1 COVID-19 variant, highlight the escalating risks to global health security. GeoVax's call to action is supported by bipartisan momentum in Congress and aligns with federal priorities for strengthening domestic manufacturing and public-private partnerships in pandemic response.
The urgency of GeoVax's message is clear: without immediate investment in U.S.-based vaccine production and a diversified stockpile, the nation's efforts to combat current and future health threats will be insufficient. For more information on GeoVax's initiatives, visit https://www.geovax.com.
